Free Teach-In with Dr. Samuel Yanuck for Clinicians

“It’s essential that natural approaches for patients with SARS-Cov2 do two things: support efficient anti-viral immune surveillance and also quiet inflammation, so there’s enough room for the inherently inflammatory process of killing pathogens to take place without moving the patient too close to the threshold of ARDS manifestation.” – Dr. Yanuck COVID-19 solutions are an…

SARS

A few additional treatment possibilities in COVID19 (SARS Cov-2) addressing furin-like cleavage and pyroptosis (caspacin-1 activation of inflammasome NLRP3)

The cytokine storm seen in SARS Cov1 and Cov2 might be due to chronic pyroptosis activation. However, known activators of NLRP3 in SARS-CoV differ from CoV2.  While SARS Cov1 and COVID19 are genetically very similar, the extraordinarily high rate of infectivity of COVID19 is unique. Prepublication research suggests the cause might be a unique furin-like cleavage site on the spike protein of Cov2 that was absent in Cov1.